Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III iptacopan versus placebo in primary IgA nephropathy
2020-001049-38Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing iptacopan with placebo (2 arms). Primary endpoint: Log-transformed ratio to baseline in urine protein-to-creatinine ratio at 9 months. Started Oct 2020; status: active.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-001049-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001049-38.